Healio

COPD care pathway use raises odds for pulmonary rehabilitation referral, home discharge

Please provide your email address to receive an email when new articles are posted on . Hospitalizations with vs. without pathway use were shorter and cost less. Significantly more ...
The Gazette

Living with COPD

This simple diagram shows a healthy lung (left) and one with chronic obstructive pulmonary disease, or COPD. (AdobeStock) Buy Photo The Gazette offers audio versions of articles using Instaread. Some ...
Healio

Roflumilast more beneficial than azithromycin for COPD exacerbations, not mortality

Please provide your email address to receive an email when new articles are posted on . Patients receiving roflumilast vs. azithromycin had a reduced risk for COPD exacerbations at 1 year but an ...
The New England Journal of Medicine

Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...
WebMD

FDA OKs Nucala for Hard-to-Treat COPD

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...
CNN

This lung disease can be dangerous for younger people, too

Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...
Seeking Alpha

Roche COPD biologic astegolimab fails in phase 3 for COPD

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...
MedPage Today

FDA Approves Mepolizumab for COPD

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), drugmaker GSK announced on Thursday. Labeling for the interleukin-5 (IL-5) ...
Monthly Prescribing Reference

FDA Approves Nucala for COPD With an Eosinophilic Phenotype

Treatment with Nucala, an interleukin-5 antagonist monoclonal antibody, significantly reduced exacerbations leading to hospitalizations and emergency department visits. The Food and Drug ...
Business Wire

Propeller Health Receives FDA Clearance to Connect Patients Using the Symbicort® Inhaler to its Digital Health Platform

MADISON, Wis.--(BUSINESS WIRE)--Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, today announced it has received 510(k) clearance from the U.S. Food ...
Medscape

Evidence Growing That GLP-1RAs May Reduce COPD Exacerbations and Risks for Other Lung Diseases

The evidence that glucose-lowering medications can improve symptoms of chronic obstructive pulmonary disease (COPD) in people with diabetes has been growing, but a few studies, including a clinical ...